Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacep.2024.03.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectrum of therapeutic options in hepatocellular carcinoma.
J Exerc Rehabil
August 2025
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Hepatocellular carcinoma (HCC) is a prevalent cancer with high mortality rates globally. This review explores various HCC treatments, including surgical resection, liver transplantation, local ablation, and systemic therapies. With advancements in surgical techniques, local therapies, and immunotherapy, the treatment paradigm for HCC is rapidly evolving.
View Article and Find Full Text PDFOutcomes and Safety of Catheter Ablation in the Elderly.
J Innov Card Rhythm Manag
August 2025
Department of Cardiology, UMass Chan Medical School - Baystate, Springfield, MA, USA.
Catheter ablation has emerged as a first-line therapy for many arrhythmias. However, data on the safety and outcomes of catheter ablation in the elderly population remain limited. Here, we aimed to study the outcomes of catheter ablation in octogenarians.
View Article and Find Full Text PDFA phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
BMC Cancer
September 2025
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Background: Anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) immunotherapy promotes systemic anti-tumor immunity through expanding neoantigen-specific CD8 + T cells, but it is less effective in patients with liver metastases. Nearly 20% of non-small cell lung cancer (NSCLC) patients develop liver metastases, and these patients are characterized by fewer and less active effector T cells. Preclinical work has shown that liver metastases cause systemic immunosuppression through siphoning neoantigen-specific CD8 + T cells from systemic circulation with subsequent macrophage-mediated intrahepatic death.
View Article and Find Full Text PDFCatheter Ablation vs. Standard Implantable Cardioverter Defibrillator Therapy in Symptomatic Brugada Syndrome: A Systematic Review and Meta-Analysis of Controlled Studies.
Med Sci (Basel)
August 2025
Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
: Catheter ablation of the arrhythmogenic substrate has emerged as a promising therapeutic strategy for symptomatic Brugada syndrome (BrS). However, high-quality comparative evidence against conventional implantable cardioverter-defibrillator (ICD)-based management remains limited. : This meta-analysis aimed to evaluate the efficacy of catheter ablation in reducing ventricular fibrillation (VF) recurrence in symptomatic BrS compared to standard therapy.
View Article and Find Full Text PDFQuantitative assessment of thermal ablation in small animal tumor models: implications for pre-clinical studies of combination treatments.
Phys Med Biol
September 2025
Department of Biomedical Engineering, The George Washington University, 5000 Science and Engineering Hall, Washington, DC 20052, United States of America.
. Radiofrequency (RF) and other thermal ablation modalities in combination with systemic therapies are the subject of investigations for the treatment of tumors at risk of recurrence after first line therapies. The potential of combined therapeutic approaches is studied largely in small animals where size constraints and tumor-specific physical characteristics may significantly influence the local heating.
View Article and Find Full Text PDF